New owners buy 46% of Genomic Valley Biotech for $445,000, trigger open offer
What's the deal? Pankaj Grover and Abhisek Gupta have agreed to buy 14,07,000 shares — a 46.06% stake — in India-listed Genomic Valley BiotechDealroom has a profile for this one. Try Dealroom → from promoter Yogesh Agrawal for US$573.1K (roughly $445,000). The purchase gives the pair control of the company and triggered a mandatory open offer to public shareholders.
What's the target? Incorporated in 2001, Genomic Valley Biotech is a BSE-listed firm working in next-generation sequencing, oncology, and AI-based healthcare diagnostics. It carries a market capitalisation of about US$1.35M and reported minimal revenue in recent quarters.
Why now? The share purchase agreement was signed on October 19, 2026, and Agrawal is selling his entire holding. Under SEBI takeover regulations, an acquisition of this size forces the buyers to offer an exit to remaining shareholders.
What changes for shareholders? The open offer covers up to 7,94,170 shares, or 26% of voting capital, at US$0.41 each in cash — the same price paid to the promoter. The offer is not conditional on minimum acceptance, and a detailed public statement is due by October 27, 2026.
The US$0.41 price matches the stock's recent close of about US$0.44, so public holders get a clean exit route but no premium. Public shareholders hold 53.94% of the company, with no institutional investors on the register.
The signal: This is a small control transfer, not a sector-shaping transaction. It stands in sharp contrast to larger Indian healthcare deals such as Sun PharmaDealroom has a profile for this one. Try Dealroom →'s planned $11.8 billion Organon acquisition — a reminder that most listed-company M&A plays out quietly, at the micro-cap end of the market.
Read more: multibagg.ai
Image credit: Centers for Disease Control and Prevention
